Orion Oyj (LON:0M2N)

Market Cap	9.11B +52.7%
Revenue (ttm)	1.42B +14.0%
Net Income	273.38M -5.6%
EPS	1.94 -5.6%
Shares Out	n/a
PE Ratio	33.34
Forward PE	19.98
Dividend	1.41 (1.90%)
Ex-Dividend Date	Oct 15, 2025

Volume	158
Average Volume	607
Open	73.90
Previous Close	74.05
Day's Range	73.90 - 74.40
52-Week Range	46.85 - 74.30
Beta	0.38
RSI	72.70
Earnings Date	Feb 12, 2026

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid art...

• Industry: Pharmaceutical Preparations
• Founded: 1917
• Employees: 4,030
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0M2N

Financial Performance

In 2024, Orion Oyj's revenue was 1.54 billion, an increase of 29.65% compared to the previous year's 1.19 billion. Earnings were 329.90 million, an increase of 52.17%.

Financial numbers in EUR